openPR Logo
Press release

Global ATR Protein Inhibitors Clinical Trials and Market Opportunity Insight 2024

07-18-2024 01:22 PM CET | Health & Medicine

Press release from: KuicK Research

Global ATR Protein Inhibitors Clinical Trials and Market

Global ATR Protein Inhibitors Clinical Trials and Market Opportunity Insight 2024 Report Highlights:

* ATR Protein Inhibitors In Clinical Trials: > 15 Drugs
* China Dominates ATR Protein Inhibitors Clinical Trials: > 60% Trials
* Highest Clinical Phase: Phase-III
* Global ATR Protein Inhibitors Clinical Pipeline By Company, Indication and Phase
* ATR Inhibitors Development Trends by Country
* Competitive Landscape

Download Report:

https://www.kuickresearch.com/report-atr-protein-inhibitors-clinical-trials

Inhibition of the Ataxia telangiectasia and Rad3 related kinase, or ATR kinase, has emerged as a promising avenue in the ever-evolving landscape of cancer pharmaceutical research. ATR is a serine/threonine-protein kinase that acts as a guardian of genomic integrity by playing a critical role in the cellular response to DNA damage. Dysregulation of ATR has been linked to various diseases, particularly cancer, and inhibiting ATR presents a novel opportunity to exploit the vulnerabilities of cancer cells and enhance the efficacy of existing therapies. No ATR inhibitors have received regulatory approval as of yet; however, with several investigational candidates in the development pipeline now entering phase II trials, these novel inhibitors are anticipated to gain more attention in the years to come.

The primary focus of ATR inhibition is in the realm of oncology. ATR inhibitors have shown promise in enhancing the effectiveness of DNA-damaging cancer therapies such as chemotherapy and radiation, making hem potential candidates for combination therapies in various cancer types such as ovarian cancer, bile duct carcinoma, breast carcinoma, small cell cancer and high grade neuroendocrine cancers among other advanced solid tumors, as well as some hematological malignancies. Some ATR-inhibiting candidates being investigated in these cancers are ATG-018, Elimusertib (BAY 1895344), Camonsertib (RP-3500), and Ceralasertib (AZD6738), which have been developed by Antengene, Bayer, Repare Therapeutics, and AstraZeneca, respectively. These candidates are now in various phases of clinical evaluation.

Recent research, however, has expanded the scope of ATR inhibitors to neurodegenerative diseases. ATR kinase has implications in maintaining neuronal genomic activity, making it a potential target for conditions like Parkinson's disease and Alzheimer's disease. Further studies are linking ATR with microbial infections, especially those caused by viruses. Along with ATM, or Ataxia-telangiectasia mutated kinase, ATR is exploited by viruses to facilitate viral replication and increase expression of viral proteins. In the case of HIV-1 and COVID-19, both of which have high infection and mortality rates, ATR inhibition has represented another promising prospect for the development of novel therapeutics to manage these diseases.

As a result, the pharmaceutical industry has invested significantly in the development of ATR inhibition, and several clinical trials are being conducted now to evaluate the efficacy of these candidates. VE-821, developed by Vertex Pharmaceuticals, was the first specific ATR inhibitor to be developed, which served as the blueprint for the development of VE-822, now licensed to Merck as Berzosertib. The drug further served as the foundation for M1774, a potent ATR inhibitor being studied by Merck in various solid cancers. Both Berzosertib and M1774 have demonstrated encouraging results in early phase clinical trials in combination with chemotherapy. Administration of these ATR inhibitors enhanced the sensitivity of cancer cells to DNA-damaging chemotherapies, which makes the elimination of cancer cells faster.

ATR inhibitors pose several benefits over other cancer therapies. As described above, ATR inhibitors sensitize cancer cells to conventional therapies, potentially reducing the required dosage and mitigating side effects. Conventional therapies are potent but also face several limitations, majorly resistance to treatment. ATR inhibition can help overcome resistance mechanisms that cancer cells development against treatment, therefore improving patient outcomes. Further, ATR inhibitors can also enable a more personalized approach to cancer treatment by targeting specific genetic vulnerabilities in patients. In the realm of neurodegenerative diseases and viral infections, ATR inhibition holds the promise of slowing or preventing disease progression and improving the quality of life of affected individuals.

Despite the optimism surrounding ATR inhibitors as outlined by their advantages over existing therapies, challenges exist such as the need for refined patient section criteria and a deeper understanding of the potential side effects. However, their future potential is vast. As ATR inhibitors continue to show promise, their integration into combination therapies is expected to become more common, potentially reshaping cancer treatment regimens. Moreover, advances in molecular profiling and genetic testing may enable a more targeted ATR inhibition.

The ongoing clinical and market trends for ATR inhibitors present a compelling narrative in the pharmaceutical domain. The novel approach to targeting DNA damage response pathways holds the promise of revolutionizing cancer treatment, as well as entering the treatment protocols for neurodegenerative and infectious diseases. With ongoing research studies revealing more about ATR kinase and its implications in different indications, it is understood the full potential of ATR inhibition is yet to be realized. As this happens, a new wave of development in the global pharmaceutical market is anticipated, which makes the ATR inhibition an exciting field.

KuicK Research
Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global ATR Protein Inhibitors Clinical Trials and Market Opportunity Insight 2024 here

News-ID: 3587848 • Views:

More Releases from KuicK Research

Multispecific Antibodies Clinical Trials By Indication Country Company Drug Class Market Forecast Insight
Multispecific Antibodies Clinical Trials By Indication Country Company Drug Clas …
Global Multispecific Antibodies Market, Drug Sales, Dosage, Price and Clinical Trials Insight 2030 Report Highlights: • Global Multispecific Antibodies Market Opportunity By 2030: > USD 50 Billion • Global Multispecific Antibodies Market Sales In 2024: > USD 12 Billion • Number Of Approved Multispecific Antibodies: 18 • Global and Regional Trends Insight • Approved Antibodies Global, Regional, Annual and Quarterly Sales Insight • Approved Antibodies Dosage and Pricing Insight • Comprehensive Insight On All Antibodies In Clinical
Gamma Delta T Cell Cancer Therapy Market Opportunity Clinical Trials Technology Platforms Insight
Gamma Delta T Cell Cancer Therapy Market Opportunity Clinical Trials Technology …
Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions: • Number Of Gamma Delta T Cell Therapies In Trials: > 30 Therapies • US & China Dominating Clinical Trials Landscape: > 20 Therapies • Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication and Phase • Gamma Delta T Cell Therapy Future Market Opportunity By Different Cancers • Insight On Clinical Platforms for Evolving
US Orphan Drugs Market Sales Clinical Trials Insight 2030
US Orphan Drugs Market Sales Clinical Trials Insight 2030
US Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage and Clinical Trials Insight 2030 Report Offering and Highlights: • US Orphan Designated Drugs Market Opportunity: > US$ 190 Billion By 2030 • Insight On FDA Designated Orphan Drugs In Clinical Trials: > 850 Orphan Drugs • Clinical Trials Insight By Company, Indication, Phase and Priority Status • Insight On FDA Designated Marketed Orphan Drugs: > 500 Orphan Drugs • Pricing and Dosage Insight: > 400 Marketed Orphan Drugs • US, Global,
US Orphan Drug Market Size Forecast 20230
US Orphan Drug Market Size Forecast 20230
US Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage and Clinical Trials Insight 2030 Report Offering and Highlights: • US Orphan Designated Drugs Market Opportunity: > US$ 190 Billion By 2030 • Insight On FDA Designated Orphan Drugs In Clinical Trials: > 850 Orphan Drugs • Clinical Trials Insight By Company, Indication, Phase and Priority Status • Insight On FDA Designated Marketed Orphan Drugs: > 500 Orphan Drugs • Pricing and Dosage Insight: >

All 5 Releases


More Releases for ATR

Introducing the ATR 150: Cross-Boundary Mastery, Leading with Intelligence
The open road beckons, but the city never sleeps. What if you didn't have to choose between them? Enter the ATR 150 [https://global.qjmotor.com/car.html?id=208], a groundbreaking machine engineered to conquer both worlds with effortless grace and intelligent power. This isn't just a scooter; it's a statement, a fusion of rugged adventure and sleek urbanity. From the very first glance, the ATR 150 commands attention. Its distinctive beak-style fender and sharp, piercing headlights
ATR Network: Decentralized private data multimodal supercomputing network
With the introduction of concepts such as international digital currency, digital silk Road, and enterprise chain transformation, the short speed of the digital economy (short cycle, stable price, fast transaction) still cannot effectively solve the security and privacy problems in data transactions and data storage. Image: https://www.getnews.info/uploads/62ca0fb3474a80e56ee60c4e5ae84049.png Image: https://www.getnews.info/uploads/241c8bd986103a85f15efee4e263d7bb.png On the basis of protecting data and privacy security, ATR Network uses neural network, deep learning and other technologies to deeply analyze heterogeneous data,
ATR: High volatility as success factor for trading.
Recently, a relevant article has been published to the issue of the average true range (ATR) and a simple moving average (SMA) trading strategy in the International Journal of Recent Scientific Research (IJRSR), by Dr. Ulrich R. Deinwallner. Dr. Ulrich R. Deinwallner has published so far several articles regarding relevant research to investment strategies for U.S. stock markets. According to the findings in his current article, excess returns
Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia and Rad3 Related Prot …
Market Research Hub Report titled 'SerineThreonine Protein Kinase ATR Pipeline Review, H1 2017'; Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1177492 Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or
Global Antenna, Transducer and Radome (ATR) Market Professional Survey Report 20 …
Summary This report studies Antenna, Transducer and Radome (ATR) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Commscope Inc. Hongke Microwave Communication Co., Ltd Ethertronics Inc. Scelectron Antenna World Inc. L-3 Communications Holding Inc. Thales
curasan AG scouts for sales partners for ATR®
Supporting wound healing and tissue regeneration through the extraction of autologous platelet-mediator-concentrate (PMC) – high patient compatibility using autologous blood – No need for centrifuges and external laboratories Kleinostheim, Germany – curasan AG, listed in the General Standard of the Frankfurt Stock Exchange (ISIN: DE 000 549 453 8), has commenced with the pre-marketing activities for the launch of its new product ATR® (Advanced Tissue Regeneration). ATR® is a standardised system